This website uses cookies. By continuing you are agreeing to our privacy policy.

Katharina Maisel, Ph.D.

Katharina Maisel
University of Maryland-College Park
Use of Immunotherapies for Treating LAM
Dalsemer Grant

Pulmonary lymphangioleiomyomatosis (LAM) is a devastating progressive disease primarily affecting women of childbearing age. In LAM patients, abnormal muscle-like cells begin to grow out of control in certain organs or tissues, especially the lungs, lymph nodes, and kidneys. Two hallmarks of LAM are expanded lymphatic vessels and an immunosuppressive microenvironment in the lungs. We will determine the effects of LAM cells on lymphatic functions, and therapeutic efficacy of immunotherapies used in combination with rapamycin, the only FDA-approved LAM treatment. This work will bring novel insights into effects of LAM on lymphatic functions and may provide new avenues for LAM treatments.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.


Breathe Easy

Give today and your tax-deductible gift will go TWICE as far for everyone who struggles to breathe.